Cutting edge: Expression of the transcription factor E74-like factor 4 is regulated by the mammalian target of...

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• Naive CD8(+) T cells are quiescent and require T cell receptor (TCR) activation to enter the cell cycle.
• Expression of E74-like factor (ELF) 4 and Krüppel-like factor 4 (KLF4) genes is inhibited upon TCR activation, facilitating T cell proliferation.

Purpose of the Study:

• To investigate the role of ELF4 in CD8(+) T cell proliferation.
• To elucidate the signaling pathways regulating ELF4 and KLF4 expression during T cell activation.
• To explore the potential of rapamycin in modulating this transcriptional network.

Main Methods:

• Gene expression analysis (e.g., qPCR, Western blot) in CD8(+) T cells.
• Analysis of signaling pathways including ERK, PI3K, and mTOR.
• Functional assays to assess T cell proliferation.
• Treatment with rapamycin to evaluate its effects on gene expression and cell cycle.

Main Results:

• ELF4 controls ERK-mediated proliferation in CD8(+) T cells by regulating dual-specificity phosphatases 1 and 5.
• The mammalian target of rapamycin (mTOR) pathway, downstream of ERK and PI3K, inhibits ELF4 and KLF4 expression in activated CD8(+) T cells.
• Rapamycin treatment modulated the expression of ELF4 and KLF4, indicating its potential to influence this transcriptional network.

Conclusions:

• ELF4 is a key regulator of CD8(+) T cell proliferation, linking TCR signaling to cell-cycle progression.
• The mTOR pathway plays a critical role in suppressing ELF4 and KLF4 during T cell activation.
• Rapamycin represents a potential therapeutic agent for modulating T cell responses by targeting this transcriptional network involved in cell-cycle regulation.